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Abstract Immunoperoxidase histochemistry is a wide-
spread method of assessing expression of biomolecules in
tissue samples. Accurate assessment of the expression lev-
els of genes is critical for the management of disease, par-
ticularly as therapy targeted to speciWc molecules becomes
more widespread. Determining the quality of preservation
of macromolecules in tissue is important to avoid false nega-
tive and false positive results. In this review we discuss (1)
issues of sensitivity (false negativity) and speciWcity (false
positivity) of immunohistochemical stains, (2) approaches
to better understanding diVerences in immunostains done
by diVerent laboratories (including the recently proposed
MISFISHIE speciWcation for tissue localization studies),
and (3) approaches to assessing the quality of preservation
of macromolecules in tissue, particularly in small biopsy
samples.
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Introduction
Tissue specimens are a source of invaluable information for
not only the diagnosis of disease, but also, to ever greater
extent, for the management of disease. Historically, tissue
biopsies, analyzed by hematoxylin and eosin stains that are
often supplemented by additional special stains, have pro-
vided information for the basic classiWcation of disease and
characterization of neoplasms. The development of immu-
nohistochemistry has provided a basis for the molecular
characterization of tumors using antibodies to localize mole-
cules expressed by tumor cells. As targeted therapy using
agents, most of which are antibody derivatives or small
drug molecules speciWc to designated molecules, have been
incorporated into clinical management, the molecular char-
acterization of tumors has become increasingly important.
The diVerential expression of molecules by tumor cells pro-
vides a basis for both prognosis and for the selection of tar-
geted therapies (Ross et al. 2004). Adding further impetus
to selecting a therapy to which a speciWc neoplasm is sensi-
tive is the risk of signiWcant side eVects. For example, ¸5%
of patients receiving Trastuzumab as anti-her2 therapy for
treating breast cancer have signiWcant cardiac toxicity,
resulting in potentially irreversible impaired cardiac pump
function (Telli et al. 2007). This unanticipated side eVect is
consequent to suppression of her2-dependent cell survival
pathways. Loss of these pathways permits the cardiotoxic
eVect of anthracyclines, which are administered concomi-
tant with Trastuzumab, to become more readily manifest
(Crone et al. 2002).
For these reasons determining the molecular phenotype
of a tumor is an increasingly more important laboratory
test. Essential to accurate characterization of the molecular
phenotype of a tumor is determining the quality of preser-
vation of macromolecules in tissue. In this short review I
will focus on tumors, the identiWcation and characterization
of tumor tissue biomarkers by immunohistochemistry, and
parameters that aVect the preservation and detection of
these macromolecules. In current practice immunoperoxi-
dase histochemistry is the method that is most widely used
to determine the molecular phenotype of tumor cells. That
immunohistochemical methods are so useful is consequent
to (1) the fact that cell and/or tissue architecture is preserved
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identiWed, and (2) the sensitivity of immunostains, i.e. sin-
gle tumor cells can serve as the basis for characterizing a
tumor.
Correspondingly, issues of characterizing, controlling,
and optimizing the quality of tissues samples has become
paramount to minimize the frequency with which “false
negative” and false positive results from molecular analysis
of tumors by immunohistochemical methods occurs. At a
basic level, assessment of biomolecule expression in tissue
deals with sensitivity of the assay (if the molecule is pres-
ent, will the assay detect it?) and speciWcity (if the molecule
is present might the assay erroneously report its presence?).
Our focus will be on the three-step indirect immunoperoxi-
dase stain, which is currently the most widely used method
for assessing gene product expression in tissue.
Sensitivity
With respect to sensitivity—is the molecule present or
absent—let us consider the following sources of decreased
sensitivity that can result in a false negative immunohisto-
chemical stain.
1. The epitopes to which antibodies are directed are too
few to be detected by light microscopy.
2. The epitopes are not available to bind the speciWc anti-
bodies despite presence of the molecule due to confor-
mation features. This is exempliWed by diVerential
staining using diVerent antibodies to MUC1 and to
endothelin.
3. Epitopes can only be made available to binding the
antibody after an antigen retrieval technique, using
either proteolytic enzymes or heating the tissue section
in a buVer.
4. The primary antibodies have binding constants that
are too low to be retained in the section during the
multiple steps of tissue processing. For example, anti-
bodies used in ELISA assays are of lower aYnity than
those used in immunohistochemical stains since the
former type of reaction is a competitive assay and the
latter reaction depends upon high aYnity binding to
survive the multiple steps of processing the tissue
section.
5. The molecule may be within a compartment of the cell
that is not accessible to the immunohistochemical
reagents. Although this limitation is typically not a
problem when using sections of tissue, immunostains
of intact cells using whole immunoglobulin molecules
that may be conjugated to other molecules such as bio-
tin, might not be able to penetrate to the compartment
of the cell in which the antigen is located.
6. Degradation of the molecule: The rate of loss of immu-
noreactivity varies with the molecule. In one study,
estrogen receptor immunoreactivity could be detected
in sections from paraYn blocks that had been stored for
up to 60 years (Camp et al. 2000). Conversely, in sec-
tions that were not paraYn-coated and stored in a nitro-
gen environment but that were exposed to ambient
atmosphere at room temperature, immunoreactivity of
keratin, estrogen receptor, p53 and Ki-67 was lost
within 3 months (DiVito et al. 2004; Jacobs et al.
1996).
7. Tissue processing: The multiple steps of tissue process-
ing aVect antigens diVerently. In one study, UCHL1
and vimentin were most susceptible to the duration and
pH of Wxation and to the type of Wxative. Conversely,
L26 was most sensitive to changes in tissue processing
(Williams et al. 1997). Another study reported that the
frequency of KI-67-positive tumor cells was depen-
dent, in part, on the nature and duration of steps in the
immunohistochemistry procedure (Mengel et al. 2002).
Understanding the chemistry of what happens to molecules
and their epitopes in tissue is important for developing bet-
ter methods for assessing the quality of protein in tissue.
For example, heating of tissue sections, typically by micro-
wave, increases the detectability of most antigens (Cuevas
et al. 1994). Although the mechanism by which epitopes
become exposed is unknown, a series of immunohisto-
chemical experiments using antibodies to nuclear, cytoplas-
mic, cell membrane, and extracellular antigens applied at a
range of diVerent pH’s and of salt concentrations provides
evidence that epitopes are variably exposed (in a molecule-
speciWc manner) by electrostatic forces that may prevent
refolding to a non-immunoreactive conformation (Emoto
et al. 2005).
Formaldehyde Wxation itself has chemical complexities
that are probably not widely known. Understanding the
chemistry of formaldehyde Wxation is a step in trying to
predict the eVect of tissue processing on immunoreactivity
of a given molecule. During formaldehyde Wxation an equi-
librium between formaldehyde, as carbonyl formaldehyde,
and methylene glycol is established. The formation of the
glycol explains why formaldehyde penetrates rapidly (as
methylene glycol) and Wxes slowly (as carbonyl formalde-
hyde). For example, 16- thick sections maximize incorpo-
ration of covalently linked formaldehyde only after 24 h at
37°C and after 48 h at 25°C (Fox et al. 1985). Conse-
quently, endogenous proteases exposed to Wxative for less
than 24 h at 37°C may still be active and capable of degrading
tissue biomarker macromolecules.
Thus, understanding the details of these two parameters
of tissue processing—epitope exposure and formaldehyde
Wxation—begins to provide a basis for establishing conditions123
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tissue.
SpeciWcity
Non-speciWcity of an immunohistochemical stain may lead
to a false positive stain, resulting in a report that the mole-
cule is expressed in that tissue, whereas, in reality, it is not.
We can subcategorize sources of non-speciWc reaction
product into immunologic and non-immunologic causes.
With respect to immunologic sources of non-speciWc
reactions:
1. The epitope may be suYciently similar to the epitope
of completely unrelated molecules, due to a combina-
tion of binding aYnity and structural homology, as to
result in high-aYnity binding of the primary antibody
to an unrelated and unintended molecule.
2. The epitope may be a non-protein moiety that is a post-
translational modiWcation common to functionally
unrelated molecules.
Non-immunologic causes leading to a false positive stain
include the following:
1. Leakage of antigen into diVerent tissue compartments.
This varies with the molecule. In a post-mortem study
of the eVect of autolysis on antigen localization, alpha-
1-antichymotrypsin, alpha-2-macroglobulin, and Wbro-
nectin were mislocalized, whereas lysozyme was not
(Fieguth et al. 1997).
2. Expression of endogenous peroxidase in cells at a suY-
ciently high level to produce a signal independent of
the immunolocalization reaction. Cells that express a
particularly high-level of peroxidase-like activity
include red blood cells and neutrophils. This source of
“false positivity” can often be obviated by pre-incuba-
tion of the sections in hydrogen peroxide.
3. Expression of biotin at suYciently high levels as to
bind the avidin–biotin–peroxidase complex of an
immunoperoxidase procedure. Renal tubular epithe-
lial cells and hepatocytes, which contain high concen-
trations of biotin, can produce a reaction product that
is misinterpreted as a positive immunoperoxidase
stain when biotin conjugated reagents are used. Meth-
ods to suppress endogenous biotin activity may not
by fully eVective in preventing this source of false
positivity.
4. Idiopathic causes: False positivity can also be associ-
ated with necrosis and with other curious artifacts, such
as nuclear staining using antibodies to the cytoskeletal
protein vimentin. There is no ready explanation for
these phenomena.
5. A frequent source of “false positivity” results from
overexposure of the tissue to the immunoperoxidase
reaction. An example is the edge eVect where tissue
lifts from the slide and both sides of the section are
exposed to the immunoperoxidase reaction.
Even if all sources of non-immunologic false positivity can
be dealt with, the question of whether speciWcity can ever
be proven remains (Swaab et al. 1977). Competition with
or pre-absorption of the antibody with excess peptide con-
trols for the antigen, demonstrating that localization of the
antibody is consistent with binding to that antigen. How-
ever, failure of pre-absorption to abolish immunoreactivity
is not necessarily evidence that the antibody binding to the
sought protein has not occurred since the conformation of
the protein in tissue might be diVerent than that of the free
peptide. Control for antibody speciWcity is provided, in
part, by immunoprecipitation and demonstration that the
precipitated protein has the biochemical characteristics of
the sought protein.
Quality of tissue
From the perspective of assessing and controlling the qua-
lity of tissue, let us Wrst consider tissue handling. Histori-
cally, the “quality” of a sample has been based on the
microscopic assessment of such features as necrosis, crush
artifact, and biologic phenomena that might aVect gene
expression such as hemorrhage and inXammation. How-
ever, there is not a good correlation between such histologi-
cal features as necrosis and retention of molecules that can
be detected by immunohistochemistry. For example, cells
types can be identiWed and characterized by immunostains
in tissue that at the light microscopic level is totally
necrotic. Our ability to predict retention of immunoreacti-
vity in such a situation is imperfect. Whether or not necrotic
tissue contains epitopes that are immunoreactive is unpre-
dictable.
Historically, the quality of RNA and DNA has been
assessed in samples of tissue large enough to analyze by,
respectively, Northern and Southern blots. Molecular
ampliWcation techniques have permitted characterization of
nucleic acids extracted from such small samples as needle
biopsies of tissue using reverse transcriptase polymerase
chain reaction. Instruments such as the Bioanalyzer (Agi-
lent Technologies, Inc., Santa Clara, CA) can assess the
quality of nucleic acids based on degree of fragmentation.
As little as 1 l of solution can be analyzed for expression
of as little as 1 ng of nucleic acid.
The lability of macromolecules to certain conditions of
tissue handling has been characterized at the nucleic acid
level. Gene expression proWles have been characterized for123
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been devitalized by clamping vessels but not yet removed
from the patient for processing) (Lin et al. 2006) and for
autolysis (while the prostate sits on a bench at room tem-
perature) (Dash et al. 2002). These proWles can be used to
“correct” expression proWles of tissue samples. Immunohis-
tochemical assessment of expression of a set of antigens in
tissue let sit at 37° C for a range of times (0, 4, 8, 12, 24, 48,
and 72 h) yields thematically similar Wndings. Although
Leu2a immunoreactivity was preserved for only 12 h, CLA
and UCHL-1 immunoreactivity was retained for at least
72 h (Pelstring et al. 1991).
However, these ischemia and autolysis proWles analyze
only two of numerous steps in tissue processing (Fig. 1).
Furthermore, the quality of RNA may not accurately reXect
levels of protein expression since expression levels of
mRNA and of the corresponding protein translation product
may diVer, for some genes up to 5-fold (Pascal et al. 2008).
Thus, these proWles do not provide a particularly good basis
for assessing the quality of protein in tissue. The assess-
ment of the quality of proteins in tissues, particularly very
small samples, is a signiWcant challenge since there is no
current method to amplify proteins for analysis. Further-
more, since expression levels of protein diVer widely in
tissue, there is no protein that can be used as a marker for
the overall quality of protein in tissue. That said, there are
speciWc gene products that have been used as markers of
extent of preservation/Wxation in buVered formalin—p27
(De Marzo et al. 2002) and vimentin (using an antibody to
an epitope of vimentin that is partially susceptible to form-
aldehyde Wxation) (Battifora 1991). These potential markers
of tissue preservation have not seen general use.
Development of the MISFISHIE standard
What does seem important as an initial step in determining
the overall quality of macromolecules in tissue studies is
identiWcation of the critical steps that inXuence gene
expression. To explicitly identify these steps we have pro-
posed a speciWcation for all tissue localization experi-
ments—by immunohistochemical and in-situ hybridization
methods (see http://www.scgap.systemsbiology.net/stan-
dards/misfishie/ and http://www.mged.sourceforge.net/mis-
fishie/) (Deutsch et al. 2008). Termed MISFISHIE (an
abbreviation of Minimum Information SpeciWcation For In
Situ Hybridization and Immunohistochemistry Experi-
ments), and developed by a large group of colleagues work-
ing in diVerent Welds of biomedicine, the speciWcation
stipulates the steps of all such experiments that should be
documented and characterized in detail (Fig. 1). The princi-
ple of this speciWcation is to ensure that the minimum
information that a researcher at a diVerent lab needs to
reproduce or evaluate the experiment is provided. MISFIS-
HIE does not specify the data format or in any manner limit
the nature of the experiment. MISFISHIE merely stipulates
what information should be communicated. Ideally these
principles are being used by authors and are looked for by
reviewers and editors in publications of such experiments.
However, this is not uniformly the case. A signiWcant num-
ber of publications in a wide range of journals fail to satisfy
MISFISHIE standards by not providing suYcient detail to
have conWdence that the experiment can be repeated, as we
found in a retrospective review of 30 published articles
(Fig. 2). Since the conclusions of so many current immuno-
histochemical studies are based on interpretations of
images, and since image interpretation is a source of
Fig. 1 Schematic of steps in tissue processing with examples of
potential sources of variance in gene expression levels. These steps are
classiWed into those steps over which the investigator has no control,
i.e. either the events occurred prior to receipt of tissue or obtaining the
tissue was obtained in a setting where clinical needs were paramount,
or those that the investigator can potentially modify123
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that all images be made available for independent interpre-
tation (Pascal et al. 2007). Although this expectation is cur-
rently onerous, given the eVort necessary to obtain the
images and the disc storage required to save the images, we
think that making images available for independent review
and interpretation will be a long-term beneWt to biomedical
science.
By applying MISFISHIE rules to experiments all poten-
tial sources of variance in tissue based experiments will, in
principle, be revealed. Although documenting all steps of
immunohistochemical experiments provides a basis for tar-
geting those parts of the procedure that are the source of
greatest variance, implementation of quality control proce-
dures is the next step. Using on slide positive and negative
control tissues (Mengel et al. 2005) and parallel immuno-
stains of tissue microarrays that contain a variety of control
tissues (Hsu et al. 2002) are ways to increase conWdence
that an immunohistochemical Wnding is accurate.
Standardization
Standardization of procedures in diVerent labs would
increase the reliability of an immunohistochemical proce-
dure. A step in addressing standardization of tissue process-
ing is to document how diVerent labs process their samples.
A component of an ongoing study by the NIH-funded Pros-
tate Cancer SPORE’s was documenting the timing for
diVerent steps of tissue processing at the SPORE sites. Data
recorded by the tissue processors illustrate the range in time
for processing tissue from ethanol into paraYn—0 to
310 min (Fig. 3). This sequence is but one set of intermedi-
ate steps in the tissue processing cycle. The eVect of this
range of processing time on antigen immunoreactivity is
being assessed. Unfortunately, documentation of the time
required for the entire sequence of tissue processing is
virtually never done due to the imprecision and impractical-
ity of being able to accurately record the time required for
many steps, such as time the tissue sits at ambient tempera-
ture on the bench before Wxation and time in formalin
before initiating tissue processing.
Although desirable, standardization of routine tissue
handling procedures and of tissue localization methods
does not appear imminent due to clinical and practical con-
siderations, which diVer by laboratory, and the absence of
compelling evidence that such standardization will be of
value. What would be of value would be developing a met-
ric to assess the quality of preservation of macromolecules
in Wxed tissue. Methods are being applied that measure
integrity of nucleic acids in Wxed tissue (Jewell et al. 2002).
Although assessment of protein integrity is a greater chal-
lenge, mass spectrometry is being used as a protein inte-
grity assessment tool (Shi et al. 2006).
“QuantiWcation” by immunoperoxidase histochemistry
The conditions necessary to ensure that tissue quality is
suYcient to minimize the possibility of false negative and
false positive immunohistochemical results pale at the
challenge posed by the goal of obtaining reliable and
reproducible quantiWcations of molecules in sections of
tissue. To truly quantify levels of gene expression by
immunohistochemistry entails developing a standard curve
for each antigen and each immunohistochemical method.
Based on a standard curve, where known (either absolute
or relative) numbers of molecules per unit of tissue (or,
ideally, per average cell), is determined at multiple con-
centrations over the range of anticipated expression level
in the tissue of interest, the expression level of the mole-
cule of interest can be calculated. However, with only rare
exceptions, expression levels of gene products are “quantiWed”
Fig. 2 Percentage of 30 randomly selected papers that would not have
satisWed the MISFISHIE speciWcation, by MISFISHIE category (key:
1 Experimental Design; 2 Biomaterials and Treatment, i.e. tissue pro-
cessing, Wxation medium, storage conditions; 3 Reporters, i.e. antibody
source, clone, concentration; 4 Staining, i.e. antigen retrieval method,
staining protocol; 5 Imaging Data, i.e. images of immunostains; 6 Im-
age Characterization, i.e. algorithm for reporting and analyzing the
immunostaining images, criteria for positivity
Fig. 3 Time to process blocks of formaldehyde-Wxed, tissue by tissue
processors at seven diVerent institutions (NIH-funded Prostate Cancer
SPORE’s) from the Wrst ethanol dehydration step through paraYn inWl-
tration (Fine SW, Trock B, Reuter VE, Ayala G, Cheville JC, Fearn P,
Jenkins RB, Knudsen BS, Loda M, Netto GJ, Said J, Shah RB, Simko
J, Troncoso P, True LD, Yang XJ, Rubin MA, DeMarzo AM (2007)
EVects of tissue processing on biomarker analysis in prostate needle
biopsies: a multi-institutional study. Annual Meeting of US–Canadian
Academy of Pathology123
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reference to a standard curve for that gene produce in that
tissue. In a study that exempliWes the use of a standard
curve, levels of a gene product were measured by correla-
ting the optical density of immunoperoxidase stained sec-
tions to the amount of the same protein, which was
extracted and measured by radioimmunoassay from an
adjacent, histologically homologous tissue sample (Gross
and Rothfeld 1985). Although developing such reference
standards is an expensive and laborious process, it is the
only way to ensure that the optical density of an immuno-
peroxidase stained section reXects gene expression level.
The challenge to using immunohistochemical stains to
quantify molecules is that sources of variance are numer-
ous (True 1988). And, yet, the issue is critical. As just one
example, the concentration of biomarker antibody appears
to dramatically aVect the apparent relationship between
her2 expression and prognosis of patients with breast can-
cer (McCabe et al. 2005).
Despite these caveats, many investigators have “quanti-
Wed” immunostains by assigning numbers to ranges of
staining intensity and summarizing the results as single
value numbers. For example, estrogen receptor (ER) immuno-
stains have been reported as continuous variables, termed
by some the H Score (McClelland et al. 1990; McCarty
et al. 1985). An assumption made in these calculations is
that these numerical values represent a continuous variable.
However, that assumption has not been validated. For
example, there is no evidence that a breast cancer express-
ing ER with an H score of 200 has twice the per tumor cell
ER content as a breast cancer with an H score of 100. The
use of letters instead of numbers would make explicit the
fact that interpretations of immunostains provide categori-
cal, not continuous, variables.
With respect to quantiWcation of gene products, house-
keeping genes have traditionally been used as reference
levels for the quantiWcation of nucleic acids (de Kok et al.
2005). In principle, the products of housekeeping genes can
serve as metrics for the quality of preservation of the
nucleic acids. However, there appears to be no single
housekeeping gene that can be relied upon to be expressed
by the range of cells in a given tissue that might be usable
as a standard to assess quality of preservation of nucleic
acids. For example, GAPDH is an androgen regulated gene
which, due to the androgen regulation nature of the gene, is
variably expressed in tissue that may be subjected to diVer-
ent androgen concentrations. There may well not be a sin-
gle, or, even, set of housekeeping genes that remains
invariant throughout diVerent conditions (Thellin et al.
1999; Jain et al. 2006). This observation is true even for
such a pure cell population as those of cell lines (Fig. 4).
Consequently, there appears to be little immediate pros-
pect that there are housekeeping proteins or sets of proteins
that can serve as a basis for assessing protein quality in tis-
sue. Furthermore, based on all the sources of variance of
immunohistochemical stains, immunohistochemistry seems
an unlikely method to assess protein integrity in tissue. To
cite one more example of how methodology can have a pro-
found aVect on extent of immunohistochemical reactivity,
diVerent antigen retrieval techniques have a variable eVect.
More cells in tissue sections that were heated prior to
immunostaining expressed vimentin immunoreactivity than
did those in sections that were treated with proteolytic
enzymes as the antigen retrieval method (Kahveci et al.
2003; Hazelbag et al. 1995).
Heterogeneity
One aspect of analyzing tissue samples that can be a major
challenge for accurate molecular phenotyping of tumors is
the heterogeneity of tumor cell phenotypes within a given
tumor. For example, assessing breast cancer tissue for
expression of her2 or of estrogen receptor in a sample of
“insuYcient” size may not accurately reXect the molecular
status of a tumor (Moeder et al. 2007; Chung et al. 2007).
The extent of heterogeneity and the challenge posed to
accurate sampling varies with both uniformity and fre-
quency of expression of the molecule. Obtaining a sample
that is representative of the status of that macromolecule in
the tumor is particularly challenging for molecules
expressed at low frequencies by cells that are not uniformly
distributed throughout a tumor. In a study of expression of
one such antigen, we tabulated the frequency of expression
of Ki-67 (Fig. 5). The fact that in one case, which exhibited
the greatest range of Ki-67-positivity (patient 2), 40 (of 100
possible) microscopic Welds would need to have been ana-
lyzed to Wnd the 90th percentile of KI-67 expression
emphasizes the challenge of dealing with heterogeneity and
in developing a strategy to sample the most clinically
relevant part of a tumor. As an aside, extent of heterogeneity
Fig. 4 Levels of mRNA (in relative units) of three putative house-
keeping genes by seven prostate cancer cell lines. Note the wide range
of expression levels of each gene (unpublished work by Mengchu Wu,
Ilsa Coleman, and Peter Nelson)123
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ple, tumor cells in breast carcinomas that vary in extent of
expression of estrogen receptor appear to be more likely to
fail systemic therapy than those tumors that exhibit more
uniform expression of the receptor (Sklarew et al. 1990).
Thus, developing a strategy for sampling a tumor for a
speciWc gene product is an important goal. One approach
would be to sample the specimen for the speciWc analyte
until the variance of the running mean of the measured
value does not exceed a pre-determined value, such as 5%
(Dunnill 1985). However, this strategy may be inadequate
for gene products expressed in very small samples at low
levels, such as Ki-67 in prostate carcinoma. Sampling algo-
rithms that report the error range need to be developed for
such clinical scenarios.
Future possibilities
Since, at least for the foreseeable future, tissue specimens
in the form of biopsies will continue to be the source of
tumor cells to be analyzed for presence and expression
level of speciWc molecules, better methods of assessing
quality of preservation of the macromolecules will need to
be developed. There are several possible solutions to this
challenge, such as:
1. Sets of housekeeping proteins that are speciWc to the
type of tissue will be developed. Given the realization
that there appears to be no single or, even, set of
housekeeping genes that can serve as a universal met-
ric for tissue quality (as discussed above), tumor-spe-
ciWc sets of proteins may have to be developed.
Complementing this development would have to be
methods to measure proteins in samples as small as
needle biopsies, which have an estimated mass of no
more than 0.000054 g.
2. A mass spectrometry method to assay the quality of
protein in a tissue may provide a better method than an
immunohistochemical stain. However, this is specula-
tive. Mass spectrometry proWles of formalin-Wxed, par-
aYn-embedded samples would have to be developed.
And, due to the variably fragmented nature of proteins
in these samples, mass spectrometry may be inadequate
to assess degree of protein integrity.
3. A better assay tool than immunoperoxidase stains may
be quantum dot-based immunohistochemical stains
(Smith et al. 2006; True and Gao 2007). Quantum dot-
based reagents provide several advantages. As light
emitting markers they have a wider dynamic range than
the optical density of immunoperoxidase stains. Since
the emitted light is intense, quantum dots can be conju-
gated directly to the primary antibodies, minimizing
the number of steps and, consequently, decreasing the
sources of variance. Finally, due to their narrow emis-
sion spectra, quantum dots of diVerent sizes (and,
hence, having diVerent emission spectra) can be conju-
gated to antibodies and multiplexed to immunohisto-
chemically characterize a single tissue section.
Even with these possibilities, optimism must be tempered
with acknowledgement that the functional state of mole-
cules often depends of post-translational modiWcations of
proteins. For example, the phosphorylated state of a protein
is often the active form of the protein. However, assaying
the extent of phosphorylation of a protein in a sample of tis-
sue is subject to many additional sources of variance. Anti-
bodies may not be immunoreactive to Wxed tissue, though
they are reactive with the soluble protein. And, the state of
phosphorylation may both be transient or, alternatively,
may be artifactually induced by the process of handling tis-
sue (Mandell 2003).
To conclude, the challenges are multiple and large. But,
the need for better metrics to assess the quality of protein
and of other macromolecules in tissue is urgent and timely.
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